EODData

MEMBERSHIP REGISTER LOG IN

FRA, 2CL: BridgeBio Pharma, Inc.

19 Dec 2025
LAST:

64.16

CHANGE:
 1.34		OPEN:
63.02		HIGH:
64.16		ASK:
0.00		VOLUME:
43
CHG(%):
2.13		PREV:
62.82		LOW:
63.02		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
19 Dec 2563.0264.1663.0264.1643
18 Dec 2562.8262.8262.8262.8260
17 Dec 2564.2064.2064.2064.2060
16 Dec 2562.4462.4462.2862.2860
15 Dec 2563.7463.7463.7463.7440
12 Dec 2562.5662.5662.5662.5640
10 Dec 2561.1661.6061.1661.6040
09 Dec 2563.3263.3263.2863.2840
08 Dec 2562.8263.6062.8263.6040
05 Dec 2563.8663.8663.4463.4440

PROFILE

Name:BridgeBio Pharma, Inc.
About:BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Sector:Healthcare
Industry:Biotechnology
Address:3160 Porter Drive, Palo Alto, CA, United States, 94304
Website:https://bridgebio.com

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-18.43 
Forward P/E:-15.11 
PEG Ratio:-0.13 
Price to Sales:29.47 
Price to Book:-5.69 
Profit Margin:-2.25 
Operating Margin:-1.13 
Return on Assets:-0.43 
Return on Equity:0.37 
Revenue:307.05M 
Shares:191.17M 
Market Cap:12.265B 

TECHNICAL INDICATORS

MA5:63.441.1%
MA10:63.171.6%
MA20:62.203.2%
MA50:55.6315.3%
MA100:48.8431.4%
MA200:40.6957.7%
STO9:98.46 
STO14:98.46 
RSI14:59.91
WPR14:-1.54 
MTM14:2.18
ROC14:0.04 
ATR:1.21 
Week High:64.200.1%
Week Low:62.283.0%
Month High:64.200.1%
Month Low:55.5257.7%
Year High:64.200.1%
Year Low:24.65160.3%
Volatility:30.29